- Home
- UAMY vs LPCN Comparison
UAMY vs LPCN Comparison
Compare UAMY & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- LPCN
- Stock Information
- Founded
- UAMY 1968
- LPCN 1997
- Country
- UAMY United States
- LPCN United States
- Employees
- UAMY N/A
- LPCN N/A
- Industry
- UAMY Metal Fabrications
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- LPCN Health Care
- Exchange
- UAMY Nasdaq
- LPCN Nasdaq
- Market Cap
- UAMY 67.5M
- LPCN 36.8M
- IPO Year
- UAMY N/A
- LPCN N/A
- Fundamental
- Price
- UAMY $0.64
- LPCN $5.49
- Analyst Decision
- UAMY
- LPCN Strong Buy
- Analyst Count
- UAMY 0
- LPCN 1
- Target Price
- UAMY N/A
- LPCN $10.00
- AVG Volume (30 Days)
- UAMY 476.5K
- LPCN 24.3K
- Earning Date
- UAMY 11-11-2024
- LPCN 11-11-2024
- Dividend Yield
- UAMY N/A
- LPCN N/A
- EPS Growth
- UAMY N/A
- LPCN N/A
- EPS
- UAMY N/A
- LPCN N/A
- Revenue
- UAMY $9,862,364.00
- LPCN $4,800,930.00
- Revenue This Year
- UAMY N/A
- LPCN N/A
- Revenue Next Year
- UAMY N/A
- LPCN N/A
- P/E Ratio
- UAMY N/A
- LPCN N/A
- Revenue Growth
- UAMY 18.08
- LPCN 8630.55
- 52 Week Low
- UAMY $0.17
- LPCN $2.34
- 52 Week High
- UAMY $0.82
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- UAMY 44.54
- LPCN 63.85
- Support Level
- UAMY $0.61
- LPCN $5.27
- Resistance Level
- UAMY $0.68
- LPCN $5.87
- Average True Range (ATR)
- UAMY 0.04
- LPCN 0.33
- MACD
- UAMY -0.01
- LPCN 0.02
- Stochastic Oscillator
- UAMY 30.62
- LPCN 71.21
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.